Vertex Pharmaceuticals Incorporated
vrtx.comTotal trials
244
Active
32
Phase 3
85
Total enrollment
35,377
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 29 of 29 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Suzetrigine | — | — | 13 | ||||
| CTX001 | — | — | — | — | — | 6 | |
| IVA | — | — | 46 | ||||
| VX-121/TEZ/D-IVA | — | — | — | — | 6 | ||
| Pregabalin | — | — | — | — | 3 | ||
| Povetacicept | — | — | — | 3 | |||
| ELX/TEZ/IVA | — | — | — | — | 23 | ||
| VNZ/TEZ/D-IVA | — | — | — | — | 4 | ||
| VX-147 | — | — | — | 3 | |||
| Tacrolimus | — | — | — | — | 2 | ||
| Biological/Vaccine | — | — | — | — | — | 1 | |
| VX-880 | — | — | — | — | — | 1 | |
| VX-670 | — | — | — | — | — | 2 | |
| VX-993 | — | — | — | — | 9 | ||
| VX-407 | — | — | — | — | 4 | ||
| VX-264 | — | — | — | — | — | 1 | |
| VX-522 mRNA therapy | — | — | — | — | — | 1 | |
| Inaxaplin | — | — | — | — | — | 1 | |
| Midazolam | — | — | — | — | — | 7 | |
| Itraconazole | — | — | — | — | — | 4 | |
| Tezacaftor | — | — | — | — | — | 2 | |
| VX-828 | — | — | — | — | — | 2 | |
| VX-118 | — | — | — | — | — | 2 | |
| Efavirenz | — | — | — | — | — | 1 | |
| Deutivacaftor | — | — | — | — | — | 1 | |
| VX-581 | — | — | — | — | — | 1 | |
| VX-272 | — | — | — | — | — | 1 | |
| VX-433 | — | — | — | — | — | 1 | |
| Bupropion | — | — | — | — | — | 1 |
Next readouts
- 2026-04-21
- 2026-04-30
- 2026-05-29
- 2026-05-31
- 2026-05-31
- 2026-07-11
- 2026-07-16
- 2026-09-17
- 2026-10-30
- 2026-11-19
Top conditions
- Cystic Fibrosis113
- Pain26
- Hepatitis C18
- Acute Pain10
- Chronic Hepatitis C6
- Rheumatoid Arthritis6
- Hemoglobinopathies6
- Sickle Cell Disease5
Frequently asked questions about Vertex Pharmaceuticals Incorporated
- How many clinical trials does Vertex Pharmaceuticals Incorporated have on ClinicalTrials.gov?
- Vertex Pharmaceuticals Incorporated is listed as the lead sponsor on 244 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Vertex Pharmaceuticals Incorporated's trials are in Phase 3?
- 85 of Vertex Pharmaceuticals Incorporated's trials are in Phase 3, spread across 29 active drug programs.
- What therapeutic areas does Vertex Pharmaceuticals Incorporated focus on?
- Vertex Pharmaceuticals Incorporated's most-studied conditions on ClinicalTrials.gov are Cystic Fibrosis, Pain, Hepatitis C, Acute Pain, Chronic Hepatitis C.
- When are Vertex Pharmaceuticals Incorporated's next clinical trial readouts?
- Vertex Pharmaceuticals Incorporated has 10 upcoming primary-completion readouts tracked here; the soonest is “A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)”, expected around 2026-04-21.